Caxton Associates LLP Vaxcyte, Inc. Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 5,978 shares of PCVX stock, worth $190,399. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,978Holding current value
$190,399% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
344Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$388 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$384 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$375 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$317 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$204 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.89B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...